CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...
Imaging-based single-cell physiological profiling holds great potential for uncovering fundamental bacterial cold shock response (CSR) mechanisms, but its application is impeded by severe focus drift ...